Bobak Azamian
2022
In 2022, Bobak Azamian earned a total compensation of $3.9M as President, Chief Executive Officer and Board Chairman at Tarsus Pharmaceuticals, a 43% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $324,500 |
|---|---|
| Option Awards | $2,077,378 |
| Salary | $590,000 |
| Stock Awards | $876,822 |
| Other | $47,580 |
| Total | $3,916,280 |
Azamian received $2.1M in option awards, accounting for 53% of the total pay in 2022.
Azamian also received $324.5K in non-equity incentive plan, $590K in salary, $876.8K in stock awards and $47.6K in other compensation.
Rankings
In 2022, Bobak Azamian's compensation ranked 886th out of 5,742 executives tracked by ExecPay. In other words, Azamian earned more than 84.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 886 out of 5,742 | 85th |
Division Manufacturing | 405 out of 3,128 | 87th |
Major group Chemicals And Allied Products | 142 out of 1,416 | 90th |
Industry group Drugs | 128 out of 1,317 | 90th |
Industry Biological Products, Except Diagnostic Substances | 26 out of 291 | 91st |
Source: SEC filing on April 26, 2023.
Azamian's colleagues
We found two more compensation records of executives who worked with Bobak Azamian at Tarsus Pharmaceuticals in 2022.